Use the hyperlinks, where available to access additional clinical trial information.
A phase I/II single arm study on the efficacy of combination Belantamab Mafodotin, Carfilzomib, Dexamethasone in patients with early relapsed multiple myeloma
Australasian Myeloma Research Consortium
Eligible patients will receive 6 cycles of the combination treatment, BelaMafKd, over the course of a 28 day cycle as tolerated. Belantamab mafodotin and Carfilzomib will be delivered by intravenous (IV) infusion on days 1 and 8 and days 1, 8 and 15 of each cycle, respectively. Oral dexamethasone will be given in weekly intervals.